Dimethyl sulfoxide (dmso)

Mouse polyclonal antibodies against human BEX4 protein were generated in C57BL/6 mice. Briefly, purified GST-BEX4 protein was injected four times intraperitoneally. Rabbit polyclonal antibodies against C-terminal polypeptides 89–106 of human BEX4 protein were commercially generated (Youngin Frontier, Seoul, Korea). The other antibodies used in this study were as follows: anti-GFP, anti-PLK1, anti-CDK1, anti-aurora A, anti-cIAP-1, anti-cdc20 (Santa Cruz Biotechnology, Dallas, TX, USA), anti-actin (Sigma-Aldrich, St. Louis, MO, USA), anti-poly(ADP-ribose) polymerase-1 (PARP), anti-cleaved-caspase 9, cleaved-caspase 7, anti-active-caspase 3, anti-phospho-threonine (p-Thr) (Cell Signaling Technology, Danvers, MA, USA), anti-aurora B (BD Biosciences PharMingen, San Diego, CA, USA), anti-securin (PTTG1; Zymed, San Francisco, CA, USA), anti-Myc (Bethyl Laboratories, Montgomery, TX, USA), and Alexa Fluor (Invitrogen, Leek, The Netherlands). The following reagents were used: MG132, cycloheximide (CHX), dimethyl sulfoxide (DMSO) (AG Scientific, San Diego, CA, USA), nocodazole (Sigma-Aldrich), and PLK1 kinase inhibitor BI2536 (Axon Medchem, Groningen, Netherlands).

The following antibodies were used: anti-Pellino-1 (F-7), anti-β-TrCP(H-85) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-actin, anti-Flag M2 (Sigma, St. Louis, MO, USA), anti-Slug, anti-Snail, anti-E-cadherin, anti-β-catenin, anti-Vimentin, anti-ERK1/2, anti-p-ERK1/2 (T202/Y204), anti-Akt, anti-p-Akt (S473), anti-GSK3β, anti-p-GSK3β (S9) (Cell Signaling Technology, Danvers, MA, USA), anti-HA, anti-Myc (Roche, Basel, Switzerland). The following reagents were used: LY294002, PD98059 (Calbiochem, San Diego, CA, USA), MG132, cycloheximide, dimethyl sulfoxide (DMSO) (AG Scientific, San Diego, CA, USA) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma), EGF, mitomycin C (Sigma) and EGFR kinase inhibitor AG1478 (Selleckchem, Houston, TX).